is highly active in tumor tissue and as such confers a degree of tumor specificity to capecitabine. The active drug 5-FU is converted in a final catabolic step to fluoro-beta-alanine (FBAL); this ...

Following conversion to 5-FU, 60–90% of capecitabine is catabolized by dihydropyrimidine dehydrogenase (DPD) ultimately to FBAL and 10–20% is excreted in urine unchanged. It has also been ...